Prognostic value of cancer stem cell marker CD133 in ovarian cancer: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 3080-3088

  Zhou, Quan ^a   Chen, Aihua ^a   Song, Huamei ^a   Tao, Jing ^a   Yang, Huaijie ^a   Zuo, Manzhen ^a  

^a Department of Gynecology and Obstetrics The People s Hospital of Three Gorges University The First People s Hospital of Yichang   (China)

Author keywords

Cancer stem cells; CD133; Ovarian cancer; Prognosis

Indexed keywords

CD133 ANTIGEN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; ETHNICITY; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PATHOLOGY; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TISSUE MICROARRAY;

EID: 84929152737     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Kipps E, Tan DS and Kaye SB. Meeting the challenge of ascites in ovarian cancer: New avenues for therapy and research. Nat Rev Cancer 2013; 13: 273-282.
3. Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, Stany MP, Rose GS, Markman M, Ozols RF, Armstrong DK and Maxwell GL. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual sidual: A Gynecologic Oncology Group study. Gynecol Oncol 2011; 122: 521-526.
4. Landrum LM, Java J, Mathews CA, Lanneau GS Jr, Copeland LJ, Armstrong DK and Walker JL. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study. Gynecol Oncol 2013; 130: 12-18.
5. Pantic I. Cancer stem cell hypotheses: Impact on modern molecular physiology and pharmacology research. J Biosci 2011; 36: 957-961.
6. O’Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, Wang T, Pu C, Wang Z, Qiao L and Duan W. Cancer stem cells: A contentious hypothesis now moving forward. Cancer Lett 2014; 344: 180-187.
7. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F and Papaccio G. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 2013; 27: 13-24.
8. Yang K, Chen XZ, Zhang B, Yang C, Chen HN, Chen ZX, Zhou ZG, Chen JP and Hu JK. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 2011; 26: 173-180.
9. Wang K, Xu J, Zhang J and Huang J. Prognostic role of CD133 expression in colorectal cancer: A meta-analysis. BMC Cancer 2012; 12: 573.
10. Chen S, Song X, Chen Z, Li X, Li M, Liu H and Li J. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One 2013; 8: e56380.
11. Ma YC, Yang JY and Yan LN. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis. Eur J Gastroenterol Hepatol 2013; 25: 1007-1016.
12. Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, Chen JP, Zhou ZG, Mo XM and Hu JK. Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. PLoS One 2013; 8: e59154.
13. Qu H, Li R, Liu Z, Zhang J and Luo R. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol 2013; 6: 2644-2650.
14. Tan Y, Chen B, Xu W, Zhao W and Wu J. Clinicopathological significance of CD133 in lung cancer: A meta-analysis. Mol Clin Oncol 2014; 2: 111-115.
15. Wu H, Qi XW, Yan GN, Zhang QB, Xu C and Bian XW. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. PLoS One 2014; 9: e100168.
16. Wang W, Chen Y, Deng J, Zhou J, Zhou Y, Wang S and Zhou J. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis. Tumour Biol 2014; 35: 9769-9775.
17. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S and Scambia G. CD133 antigen expression in ovarian cancer. BMC Cancer 2009; 9: 221.
18. Kim KH, Kang YJ, Jo JO, Ock MS, Moon SH, Suh DS, Yoon MS, Park ES, Jeong N, Eo WK, Kim HY and Cha HJ. DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers. Biochem Biophys Res Commun 2014; 447: 315-322.
19. HZ L, YS B, WW L and RY L. Expression and clinical significance of CD133 and Notch1 gene in epithelial ovarian carcinoma. Chin J Clinicians (Electronics Edition) 2012; 6: 2086-2188.
20. L L. Expression and clinical significance Cancer stem cell marker nestin and CD-133 in ovarian cancer. Chin J Postgrad Med 2014; 37: 60-62.
21. Qin Q, Sun Y, Fei M, Zhang J, Jia Y, Gu M, Xia R, Chen S and Deng A. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Neoplasma 2012; 59: 310-315.
22. Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Fruscio R, Sina F, Torri V, Broggini M and Damia G. ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res 2013; 3: 221-229.
23. Zhai YX, LH Z, L Z and YS W. The expression and significance of LGR5 and CD133 as the stem cell markers on the ovarian cancer. Chin J Lab Diagn 2013; 17: 1598-1601.
24. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I and Liu J. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 2012; 25: 456-464.
25. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D and Kunz-Schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013; 229: 355-378.
26. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR and Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27: 2875-2883.
27. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS and Buckanovich RJ. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71: 3991-4001.
28. Irollo E and Pirozzi G. CD133: to be or not to be, is this the real question? Am J Transl Res 2013; 5: 563-581.
29. Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee CW and Lee CC. CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis. BMC Gastroenterol 2012; 12: 95.
30. Yu L, Deng L, Li J, Zhang Y and Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 2013; 128: 391-396.
31. Liu S, Liu C, Min X, Ji Y, Wang N, Liu D, Cai J and Li K. Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. PLoS One 2013; 8: e81050.